A global catalog shows how creatures across the tree of life balance rigidity with flexibility in remarkably consistent ways ...

Conspiracies might be fun to entertain. But the "big lie" tactic destroys your judgment and credibility. Find out why, and ...

Why we procrastinate has less to do with willpower than with how flexibly our brains handle stress and discomfort - and the ...

One of the earliest mentions of New Year's resolutions appeared in a Boston newspaper in 1813. But the practice itself can be ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Here's why Metallica stopped using guitar amps live, according to James Hetfield's guitar tech. Metallica fans may or may not have even noticed that the rockers don't have a bunch of amps lined up ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...